Proteinase activity in human and murine saliva as a biomarker for proteinase inhibitor efficacy

Clinical Cancer Research

Volumn 10, Issue 23, 2004, Pages 7865-7874

  Fingleton, Barbara ^a   Menon, Ramkumar ^b   Carter, Kathy J ^a   Overstreet, P Dawn ^c   Hachey, David L ^c   Matrisian, Lynn M ^a   McIntyre, J Oliver ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTENNIAL MEDICAL CENTER   (United States)

^c VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B 428; BATIMASTAT; BIOLOGICAL MARKER; FLUORESCENT DYE; GELATINASE; GELATINASE B; MATRIX METALLOPROTEINASE INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEINASE; PROTEINASE INHIBITOR; REBIMASTAT; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SALIVA LEVEL; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; ENZYME SUBSTRATE; FEMALE; FLUORESCENCE; HUMAN; MALE; MASS SPECTROMETRY; MODULATION; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; SALIVA ANALYSIS;

AMIDINES; AMYLASES; ANIMALS; BIOLOGICAL MARKERS; BLOOD PROTEINS; CHROMATOGRAPHY, LIQUID; ENDOPEPTIDASES; FEMALE; HUMANS; IMIDAZOLES; MALE; MASS SPECTROMETRY; MATRIX METALLOPROTEINASE 9; METALLOENDOPEPTIDASES; MICE; ORGANIC CHEMICALS; PHENYLALANINE; PROTEASE INHIBITORS; SALIVA; THIOPHENES; URINARY PLASMINOGEN ACTIVATOR;

EID: 9744260349     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1252     Document Type: Article

References (57)

1. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (Wash DC) 2002;295:2387-92.
2. Fingleton B. Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects. Expert Opin Ther Targets 2003;7:385-97.
3. Pavlaki M, Zucker S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev 2003;22:177-203.
4. Laskowski M Jr, Kato I. Protein inhibitors of proteinases. Annu Rev Biochem 1980;49:593-626.
5. Bode W, Fernandez-Catalan C, Nagase H, Maskos K. Endoproteinase-protein inhibitor interactions. APMIS 1999;107:3-10.
6. Colburn WA, Lee JW. Biomarkers, validation and pharmacokinetic- pharmacodynamic modelling. Clin Pharmacokinet 2003;42:997-1022.
7. Nemunaitis J, Poole C, Primrose J, et al. Combined analysis of studies of the effects of the matrix metalloproteinase inhibitor marimastat on serum tumor markers in advanced cancer: selection of a biologically active and tolerable dose for longer-term studies. Clin Cancer Res 1998;4:1101-9.
8. Wojtowicz-Praga S, Tonri J, Johnson M, et al. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J Clin Oncol 1998;16:2150-6.
9. Cral M, Beerepoot LV, Stokvis E, et al. Clinical pharmacokinetics, pharmacodynamics and metabolism of the novel matrix metalloproteinase inhibitor ABT-518. Cancer Chemother Pharmacol 2002;50:473-8.
10. Rizvi NA, Humphrey JS, Ness EA, et al. A phase I study of oral BMS-275291, a novel nonhydroxamate sheddase-sparing matrix metalloproteinase inhibitor, in patients with advanced or metastatic cancer. Clin Cancer Res 2004;10:1963-70.
11. Whittaker M, Floyd CD, Brown P, Gearing AJH. Design and therapeutic application of matrix metalloproteinase inhibitors. Chem Rev 1999;99:2735-76.
12. Towle MJ, Lee A, Maduakor EC, et al. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor. Cancer Res 1993;53:2553-9.
13. Xing RH, Mazar A, Henkin J, Rabbani SA. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428. Cancer Res 1997;57:3585-93.
14. Rabbani SA, Harakidas P, Davidson DJ, Henkin J, Mazar AP. Prevention of prostate-cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator (uPA). Int J Cancer 1995;63:840-5.
15. McIntyre JO, Fingleton B, Wells KS, et al. Development of a novel fluorogenic proteolytic beacon for in vivo detection and imaging of tumour-associated matrix metalloproteinase-7 activity. Biochem J 2004;377:617-28.
16. Mellanen L, Salo T, Ingman T, et al. 72-kDa and 92-kDa gelatinases in saliva of patients with human immunodeficiency virus infection. Acta Odontol Scand 1998;56:135-42.
17. Mellanen L, Ingman T, Lahdevirta J, et al. Matrix metalloproteinases-1, -3 and -8 and myeloperoxidase in saliva of patients with human immunodeficiency virus infection. Oral Dis 1996;2:263-71.
18. Ingman T, Tervahartiala T, Ding Y, et al. Matrix metalloproteinases and their inhibitors in gingival crevicular fluid and saliva of periodontitis patients. J Clin Periodontol 1996;23:1127-32.
19. Uitto VJ, Overall CM, McCulloch C. Proteolytic host cell enzymes in gingival crevice fluid. Periodontol 2000 2003;31:77-104.
20. Amour A, Knight CG, Webster A, et al. The in vitro activity of ADAM-10 is inhibited by TIMP-1 and TIMP-3. FEBS Lett 2000;473:275-9.
21. Amour A, Slocombe PM, Webster A, et al. TNF-alpha converting enzyme (TACE) is inhibited by TIMP-3. FEBS Lett 1998;435:39-44.
22. Poulaki V. BMS-275291. Bristol-Myers Squibb. Curr Opin Investig Drugs 2002;3:500-4.
23. Halinen S, Sorsa T, Ding Y, et al. Characterization of matrix metalloproteinase (MMP-8 and -9) activities in the saliva and in gingival crevicular fluid of children with Down's syndrome. J Periodontol 1996;67:748-54.
24. Westerlund U, Ingman T, Lukinmaa PL, et al. Human neutrophil gelatinase and associated lipocalin in adult and localized juvenile periodontitis. J Dent Res 1996;75:1553-63.
25. Hanemaaijer R, Visser H, Konttinen YT, Koolwijk P, Verheijen JH. A novel and simple immunocapture assay for determination of gelatinase-B (MMP-9) activities in biological fluids: saliva from patients with Sjogren's syndrome contain increased latent and active gelatinase-B levels. Matrix Biol 1998;17:657-65.
26. Wallace LJ, Partlow LM. Alpha-adrenergic regulation of secretion of mouse saliva rich in nerve growth factor. Proc Natl Acad Sci USA 1976;73:4210-4.
27. Crawford PC, Clark WB. Fimbria-specific antibodies in serum and saliva of mice immunized with Actinomyces viscosus T14V fimbriae. Infect Immun 1986;54:507-15.
28. Burhenne J, Riedel KD, Martin-Facklam M, Mikus G, Haefeli WE. Highly sensitive determination of saquinavir in biological samples using liquid chromatography-tandem mass spectrometry. J Cnromatogr B Analyt Technol Biomed Life Sci 2003;784:233-42.
29. Hugen PW, Burger DM, de Graaff M, et al. Saliva as a specimen for monitoring compliance but not for predicting plasma concentrations in patients with HIV treated with indinavir. Ther Drug Monit 2000;22:437-45.
30. Hoetelmans RM, van Essenberg M, Profijt M, et al. High-performance liquid Chromatographic determination of ritonavir in human plasma, cerebrospinal fluid and saliva. J Chromatogr B Biomed Sci Appl 1998;705:119-26.
31. Hoetelmans RM, van Essenberg M, Meenhorst PL, Mulder JW, Beijnen JH. Determination of saquinavir in human plasma, saliva, and cerebrospinal fluid by ion-pair high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl 1997;698:235-41.
32. Nordstrom D, Lindy O, Lauhio A, et al. Anti-collagenolytic mechanism of action of doxycycline treatment in rheumatoid arthritis. Rheumatol Int 1998;17:175-80.
33. Cianfrocca M, Cooley TP, Lee JY, et al. Matrix metalloproteinase inhibitor Col-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study. J Clin Oncol 2002;20:153-9.
34. Blomqvist C, Risteli L, Risteli J, et al. Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma. Br J Cancer 1996;73:1074-9.
35. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 1994;40:2022-5.
36. Delaisse JM, Andersen TL, Engsig MT, et al. Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities. Microsc Res Tech 2003;61:504-13.
37. Blomqvist C, Elomaa I, Virkkunen P, et al. The response evaluation of bone metastases in mammary carcinoma. The value of radiology, scintigraphy, and biochemical markers of bone metabolism. Cancer (Phila) 1987;60:2907-12.
38. Garnero P, Ferreras M, Karsdal MA, et al. The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 2003;18:859-67.
39. Chan AO, Lam SK, Chu KM, et al. Soluble E-cadherin is a valid prognostic marker in gastric carcinoma. Gut 2001;48:808-11.
40. Karayiannakis AJ, Syrigos KN, Savva A, et al. Serum E-cadherin concentrations and their response during laparoscopic and open cholecystectomy. Surg Endosc 2002;16:1551-4.
41. Garcia-Velasco JA, Mulayim N, Kayisli UA, Arici A. Elevated soluble Fas ligand levels may suggest a role for apoptosis in women with endometriosis. Fertil Steril 2002;78:855-9.
42. Mizutani Y, Yoshida O, Ukimura O, et al. Prognostic significance of a combination of soluble fas and soluble fas ligand in the serum of patients with ta bladder cancer. Cancer Biother Radiopharm 2002;17:563-7.
43. Bhide VM, Smith L, Overall CM, Birek P, McCulloch CA. Use of a fluorogenic septapeptide matrix metalloproteinase assay to assess responses to periodontal treatment. J Periodontol 2000;71:690-700.
44. Lee W, Aitken S, Kulkarni G, et al. Collagenase activity in recurrent periodontitis: relationship to disease progression and doxycycline therapy. J Periodontal Res 1991;26:479-85.
45. Gangbar S, Overall CM, McCulloch CA, Sodek J. Identification of polymorphonuclear leukocyte collagenase and gelatinase activities in mouth rinse samples: correlation with periodontal disease activity in adult and juvenile periodontitis. J Periodontal Res 1990;25:257-67.
46. Mancini S, Romanelli R, Laschinger CA, et al. Assessment of a novel screening test for neutrophil collagenase activity in the diagnosis of periodontal diseases. J Periodontol 1999;70:1292-302.
47. Korostoff JM, Wang JF, Sarment DP, et al. Analysis of in situ protease activity in chronic adult periodontitis patients: expression of activated MMP-2 and a 40 kDa serine protease. J Periodontol 2000;71:353-60.
48. Sarment DP, Korostoff J, D'Angelo M, et al. In situ localization and characterization of active proteases in chronically inflamed and healthy human gingival tissues. J Periodontol 1999;70:1303-12.
49. van Strijp AJ, Jansen DC, DeGroot J, ten Cate JM, Everts V. Host-derived proteinases and degradation of dentine collagen in situ. Caries Res 2003;37:58-65.
50. Dickinson DP. Cysteine peptidases of mammals: their biological roles and potential effects in the oral cavity and other tissues in health and disease. Crit Rev Oral Biol Med 2002;13:238-75.
51. Turan T, Demir S, Aybek H, et al. Free and total prostate-specific antigen levels in saliva and the comparison with serum levels in men. Eur Urol 2000;38:550-4.
52. Kishi T, Soosaipillai A, Grass L, et al. Development of an immunofluorometric assay and quantification of human kallikrein 7 in tissue extracts and biological fluids. Clin Chem 2004;50:709-16.
53. Lovgren J, Valtonen-Andre C, Marsal K, Lilja H, Lundwall A. Measurement of prostate-specific antigen and human glandular kallikrein 2 in different body fluids. J Androl 1999;20:348-55.
54. Hernandez CC, Donadi EA, Reis ML. Kallikreins and kininogens in saliva and plasma of patients presenting with rheumatoid arthritis. Scand J Rheumatol 2002;31:38-40.
55. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001;17:463-516.
56. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, et al. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 1999;274:13066-76.
57. Romanelli R, Mancini S, Laschinger C, et al. Activation of neutrophil collagenase in periodontitis. Infect Immun 1999;67:2319-26.